LFIA rapid test market seen reaching $8.67 billion by 2030

The global lateral flow immunoassay rapid test market is projected to grow from $7.17 billion in 2025 to $8.67 billion by 2030, driven by chronic disease screening, point-of-care testing and self-testing demand. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - LFIA-based rapid tests give healthcare providers and patients fast, low-cost diagnostics for infectious disease screening, chronic disease monitoring and self-testing. - The market outlook points to stronger demand for decentralized diagnostics as health systems push earlier detection and broader access to testing.

What happened: - The Business Research Company projected the LFIA-based rapid test market will grow from $7.17 billion in 2025 to $7.31 billion in 2026. - The market is forecast to reach $8.67 billion by 2030, growing at a 4.3% compound annual growth rate. - The report was released Aug. 13, 2026, from London. - Download a free sample of the report.

The details: - LFIA rapid tests are diagnostic devices that detect specific targets such as pathogens or biomarkers in bodily samples. - The tests can use blood, urine, saliva, sweat and other patient samples. - Historical growth from 2025 to 2026 was estimated at 2.0%. - Growth in that period was linked to rapid infectious disease screening, pregnancy and fertility testing, point-of-care diagnostics, lower-cost tests and public health screening programs. - Future growth is expected to be supported by investment in decentralized diagnostics, expansion of self-testing, higher demand for cardiac and toxicology tests, more digital health integration and earlier disease detection. - Chronic diseases are a major driver because LFIA tests support early detection, point-of-care use, fast results, regular monitoring and lower healthcare costs. - The UK National Health Service reported in June 2024 that 3,615,330 people registered with general practitioners had non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022. - The full market report is available here.

Between the lines: - The forecast suggests LFIA demand is shifting from a pandemic-era testing model toward broader routine use in chronic care, home testing and decentralized care settings. - North America’s lead reflects established healthcare infrastructure and adoption of point-of-care technology. - Asia-Pacific’s expected growth suggests faster uptake where healthcare access, diagnostic investment and self-testing demand are expanding. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspot infographics, key technology analysis and future trend analysis.

What's next: - The market is expected to keep expanding as chronic disease rates rise and more testing moves closer to patients. - Self-testing, digital health integration and decentralized diagnostics are likely to remain the main growth themes through 2030. - The Business Research Company provided contact details for expert inquiries, including Saumya Sahay and marketing@tbrc.info. - The company also listed its social media channels on LinkedIn, Facebook and X.